396 results
Page 3 of 20
8-K
EX-1.1
im8a7fnwndf0w
12 May 22
Entry into a Material Definitive Agreement
8:31am
424B5
mlfvt80
12 May 22
Prospectus supplement for primary offering
8:30am
8-K
ia1q2z1d
22 Apr 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:03pm
424B3
fet2rlf8vk7x5
27 Dec 21
Prospectus supplement
5:01pm
8-K
EX-10.1
pbsd0f20ni6gr
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
8-K
EX-10.2
ys12 mbh055ciret
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
8-K
EX-10.1
c1v xbtmvq
24 Nov 21
Entry into a Material Definitive Agreement
7:27am